Clinuvel Pharmaceuticals Ltd
XBER:UR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clinuvel Pharmaceuticals Ltd
XBER:UR9
|
AU |
|
E
|
Eventbrite Inc
XBER:EB4
|
US |
|
Soltec Power Holdings SA
MAD:SOL
|
ES |
|
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
US |
|
V
|
Vantage Equities Inc
XPHS:V
|
PH |
|
U
|
United Lithium Corp
CNSX:ULTH
|
CA |
|
E
|
East Japan Railway Co
F:EJR
|
JP |
|
C
|
Compagnie de Saint Gobain SA
F:GOB
|
FR |
|
J
|
Jeronimo Martins SGPS SA
ELI:JMT
|
PT |
|
SPS Commerce Inc
NASDAQ:SPSC
|
US |
Wall St Price Targets
UR9 Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for UR9 is 12.83 EUR with a low forecast of 5.86 EUR and a high forecast of 26.12 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UR9's stock price target?
Price Target
12.83
EUR
According to Wall Street analysts, the average 1-year price target for UR9 is 12.83 EUR with a low forecast of 5.86 EUR and a high forecast of 26.12 EUR.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
12%
The compound annual growth rate for Pre-Tax Income over the next 4 years is 12%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.
